Rufinamide: CGP 33101, E 2080, RUF 331, Xilep

Drugs in R and D

Volumn 6, Issue 4, 2005, Pages 249-252

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; LEAD; MESTRANOL PLUS NORETHISTERONE; PHENYTOIN; RUFINAMIDE; SODIUM; TRIAZOLE DERIVATIVE; VALPROIC ACID;

ACCURACY; ACTION POTENTIAL; ANTICONVULSANT ACTIVITY; CELL MEMBRANE; CLINICAL TRIAL; DIPLOPIA; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MECHANISM; DRUG STABILITY; EPILEPSY; EUROPE; FATIGUE; FOCAL EPILEPSY; HEADACHE; HEALTH SERVICE; HUMAN; JAPAN; LENNOX GASTAUT SYNDROME; LICENSING; MARKET; MOLECULAR STABILITY; NAUSEA; NEUROPATHIC PAIN; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; SUBSTITUTION REACTION; TONIC CLONIC SEIZURE; TREMOR; UNITED STATES;

ANTICONVULSANTS; CLINICAL TRIALS; DRUG INTERACTIONS; DRUGS, INVESTIGATIONAL; EPILEPSY; HUMANS; TRIAZOLES;

EID: 22244452355     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200506040-00010     Document Type: Review

References (11)

1. Eisai Co Ltd. Eisai Announces In-Licensing Agreement with Novartis for Rufinamide, A New Antiepileptic Agent. Media Release: 9 Feb 2004. Available from URL: http://www.eisai.com
2. Eisai Co Ltd. Eisai Announces Submission of Marketing Authorization Application of the Antiepileptic Agent Inovelon in Europe. Media Release: 30 Mar 2005. Available from URL: http://www.eisai.co.jp
3. Cheung WK, Kianifard F, Wong A, et al. Intra- and inter-subject variabilities of CGP 33101 after replicate single oral doses of two 200-mg tablets and 400-mg suspension. Pharmaceutical Research 12: 1878-1882, Dec 1995
4. Waldmeier F, Gschwind H-P, Rouan M-C. Metabolism of the new anticonvulsive trial drug rufinamide (CGP 33101) in healthy male volunteers. Epilepsia 37 (Suppl. 5): 167, 1996
5. Pålhagen S, Canger R, Henriksen O, et al. Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. Epilepsy Research 43: 115-124, Feb 2001
6. Chang S-W, Choi L, Karoplchyk MA. A pharmacokinetic evaluation of rufinamide in elderly and younger subjects. Epilepsia 39 (Suppl. 6): 59, 1998
7. Sachdeo RC, Rosenfeld WE, Choi L. Pharmacokinetics and safety of adjunctive rufinamide therapy in pediatric patients with epilepsy. Epilepsia 39 (Suppl. 6): 166-167, 1998
8. Litzinger MJ, Hanny A. Safety and efficacy of open-label rufinamide as adjunctive therapy in pediatric patients with partial seizures. Epilepsia 40 (Suppl. 7): 114 (plus poster), 1999
9. Vazquez BR, Sachedo R, Maxoutova AL, et al. Efficacy and safety of rufinamide as adjunctive therapy in adult patients with therapy-resistant partial-onset seizures. Epilepsia 41 (Suppl. 7): 255, 2000
10. Kapeghian JC, Madan A, Parkinson A. Evaluation of rufinamide (CGP 33101), a novel anticonvulsant, for potential drug interactions in vitro. Epilepsia 37 (Suppl. 5): 26, 1996
11. Svendsen KD, Choid L, Chen B-L. Single-center, open-label, multiple-dose pharmacokinetic trial investigating the effect of rufinamide administration on Ortho-Novum 1/35 in healthy women. Epilepsia 39 (Suppl. 6): 59, 1998